BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16738800)

  • 1. CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies.
    Harro J
    Amino Acids; 2006 Oct; 31(3):215-30. PubMed ID: 16738800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The NPY system in stress, anxiety and depression.
    Heilig M
    Neuropeptides; 2004 Aug; 38(4):213-24. PubMed ID: 15337373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropeptide Y attenuates anxiety- and depression-like effects of cholecystokinin-4 in mice.
    Desai SJ; Borkar CD; Nakhate KT; Subhedar NK; Kokare DM
    Neuroscience; 2014 Sep; 277():818-30. PubMed ID: 25106129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptide Y and its receptor subtypes specifically modulate rat peritoneal macrophage functions in vitro: counter regulation through Y1 and Y2/5 receptors.
    Dimitrijević M; Stanojević S; Vujić V; Beck-Sickinger A; von Hörsten S
    Regul Pept; 2005 Jan; 124(1-3):163-72. PubMed ID: 15544855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a new neuropeptide Y Y5 agonist radioligand: [125I][cPP(1-7), NPY(19-23), Ala31, Aib32, Gln34]hPP.
    Dumont Y; Thakur M; Beck-Sickinger A; Fournier A; Quirion R
    Neuropeptides; 2004 Aug; 38(4):163-74. PubMed ID: 15337369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Y5 neuropeptide Y receptor overexpression in mice neither affects anxiety- and depression-like behaviours nor seizures but confers moderate hyperactivity.
    Olesen MV; Christiansen SH; Gøtzsche CR; Holst B; Kokaia M; Woldbye DP
    Neuropeptides; 2012 Apr; 46(2):71-9. PubMed ID: 22342800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased brain neuropeptide Y1 and Y2 receptor binding in NPY knock out mice does not result in increased receptor function.
    Gehlert DR; Shaw JL
    Peptides; 2007 Feb; 28(2):241-9. PubMed ID: 17208335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuropeptide Y suppresses absence seizures in a genetic rat model primarily through effects on Y receptors.
    Morris MJ; Gannan E; Stroud LM; Beck-Sickinger AG; O'Brien TJ
    Eur J Neurosci; 2007 Feb; 25(4):1136-43. PubMed ID: 17331209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of cholecystokinin-A and cholecystokinin-B receptors in anxiety.
    Hernandez-Gómez AM; Aguilar-Roblero R; Pérez de la Mora M
    Amino Acids; 2002; 23(1-3):283-90. PubMed ID: 12373548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning and characterization of rabbit neuropeptide Y receptor subtypes.
    Umeda T; Kanatani A; Iwaasa H
    Peptides; 2009 Aug; 30(8):1441-7. PubMed ID: 19481128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
    Farook JM; Zhu YZ; Wang Q; Moochhala SM; Lee L; Wong PT
    Neurosci Lett; 2004 Apr; 358(3):215-9. PubMed ID: 15039119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropeptide Y induces gonadotropin-releasing hormone gene expression directly and through conditioned medium from mHypoE-38 NPY neurons.
    Dhillon SS; Gingerich S; Belsham DD
    Regul Pept; 2009 Aug; 156(1-3):96-103. PubMed ID: 19371763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms.
    Gao J; Ghibaudi L; Hwa JJ
    Am J Physiol Endocrinol Metab; 2004 Oct; 287(4):E706-11. PubMed ID: 15187000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular evolution of NPY receptor subtypes.
    Larhammar D; Salaneck E
    Neuropeptides; 2004 Aug; 38(4):141-51. PubMed ID: 15337367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complex plastic changes in the neuropeptide Y system during ethanol intoxication and withdrawal in the rat brain.
    Olling JD; Ulrichsen J; Christensen DZ; Woldbye DP
    J Neurosci Res; 2009 Aug; 87(10):2386-97. PubMed ID: 19267419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Region specific galanin receptor/neuropeptide Y Y1 receptor interactions in the tel- and diencephalon of the rat. Relevance for food consumption.
    Parrado C; Díaz-Cabiale Z; García-Coronel M; Agnati LF; Coveñas R; Fuxe K; Narváez JA
    Neuropharmacology; 2007 Feb; 52(2):684-92. PubMed ID: 17087983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central functions of neuropeptide Y in mood and anxiety disorders.
    Wu G; Feder A; Wegener G; Bailey C; Saxena S; Charney D; Mathé AA
    Expert Opin Ther Targets; 2011 Nov; 15(11):1317-31. PubMed ID: 21995655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research in anxiety disorders: from the bench to the bedside.
    Garner M; Möhler H; Stein DJ; Mueggler T; Baldwin DS
    Eur Neuropsychopharmacol; 2009 Jun; 19(6):381-90. PubMed ID: 19327970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze.
    Bacchi F; Mathé AA; Jiménez P; Stasi L; Arban R; Gerrard P; Caberlotto L
    Peptides; 2006 Dec; 27(12):3202-7. PubMed ID: 16959374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between NPY and CRF in the amygdala to regulate emotionality.
    Sajdyk TJ; Shekhar A; Gehlert DR
    Neuropeptides; 2004 Aug; 38(4):225-34. PubMed ID: 15337374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.